Profound Medical First Quarter 2025 Earnings: Misses Expectations

Profound Medical (TSE:PRN) First Quarter 2025 Results

Key Financial Results

• Revenue: US$2.62m (up 37% from 1Q 2024).
• Net loss: US$10.7m (loss widened by 73% from 1Q 2024).
• US$0.36 loss per share (further deteriorated from US$0.26 loss in 1Q 2024).

Our free stock report includes 2 warning signs investors should be aware of before investing in Profound Medical. Read for free now.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Profound Medical Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 22%. Earnings per share (EPS) also missed analyst estimates by 24%.

Looking ahead, revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in North America.

Performance of the market in Canada.

The company's shares are down 13% from a week ago.

Risk Analysis

We should say that we've discovered 2 warning signs for Profound Medical that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.